Edition:
India

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.95USD
2:29am IST
Change (% chg)

$0.10 (+2.60%)
Prev Close
$3.85
Open
$3.88
Day's High
$4.03
Day's Low
$3.73
Volume
15,163
Avg. Vol
20,610
52-wk High
$12.09
52-wk Low
$3.10

Chart for

About

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The... (more)

Overall

Beta: 0.45
Market Cap(Mil.): $131.10
Shares Outstanding(Mil.): 18.65
Dividend: --
Yield (%): --

Financials

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

22 Dec 2017

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON, Dec 22 Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

22 Dec 2017

BRIEF-Aspen Announces Strategic Partnership With CGB Diversified Services

* ASPEN ANNOUNCES STRATEGIC PARTNERSHIP WITH CGB DIVERSIFIED SERVICES

19 Dec 2017

BRIEF-Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics

* EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2yOFk6N Further company coverage:

08 Dec 2017

BRIEF-Novelion Therapeutics Appoints Michael Price As CFO

* NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

04 Dec 2017

BRIEF-Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice

* Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice

21 Nov 2017

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

21 Nov 2017

UPDATE 1-U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

21 Nov 2017

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A U.S. judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes into its marketing of a cholesterol drug, saying it was "not in the public interest."

21 Nov 2017

BRIEF-Novelion Therapeutics says CEO resigns, posts Q3 results

* Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change

09 Nov 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,439 +48.00
Pfizer Inc. (PFE.N) $37.18 +0.58
Novartis AG (NOVN.S) CHF83.24 -0.32
Merck & Co., Inc. (MRK.N) $62.03 -0.04
Roche Holding Ltd. (ROG.S) CHF233.35 -2.65
Roche Holding Ltd. (RO.S) CHF235.80 -3.60
Bayer AG (BAYGn.DE) €103.60 -0.92
Bayer AG (BAYE.F) -- --
AstraZeneca plc (AZN.L) 4,990.50 -58.50
Allergan, Inc. (AGN.N) $176.72 -1.94

Earnings vs. Estimates